More stories
The Psychedelic News Feed: October 27 – November 02, 2025
This is an archived version of our Psychedelic News Feed. Explore the live Feed and receive a weekly digest to your inbox by joining...
Compass Pathways Accelerates Psilocybin Launch Timeline by 9-12 Months
This morning, Compass Pathways announced that it is preparing to launch its psilocybin therapy (COMP360) for treatment-resistant depression (TRD) at least nine months earlier...
CLOSING RECEPTION Travis Gillan’s Revelator
CLOSING RECEPTION for “Revelator” – a solo exhibition by Travis Gillan Featuring moderated artist talk with Travis Gillan & Joe Moore of Psychedelics today...
Pα+ Psychedelic Bulletin #212: Delix Posts Early Efficacy Signal; NRx Wants FDA to Ban...
On Tuesday, Delix Therapeutics announced positive topline data from a small Phase Ib study of DLX-001 in major depressive disorder (MDD). DLX-001, also known...
Q3’25 Psychedelic Lobbying Update
Each quarter, we provide a look at federal lobbying disclosures by psychedelic drug developers and nonprofits. That data is a lagging indicator, especially as...
Jennifer Espenscheid — Art as a Practice, Psychedelics as a Teacher
Artist, builder, and podcast host Jennifer Espenscheid joins Joe Moore for a rich conversation on creativity, process, and the spiritual dimensions of making art....
The Psychedelic News Feed: October 20 – 26, 2025
This is an archived version of our Psychedelic News Feed. Explore the live Feed and receive a weekly digest to your inbox by joining...
Pα+ Psychedelic Bulletin #211: AbbVie Officially Enters Psychedelics; atai-Beckley’s 5-MeO-DMT Scores Breakthrough Therapy Designation;...
AbbVie has completed its acquisition of Gilgamesh Pharmaceuticals’ lead candidate, bretisilocin, the large pharmaceutical company announced last Friday. The associated press release described the...
Q3’25 Investor Survey: What are Investors Most Concerned About?
Earlier, we shared the high-level results of our Q3’25 Psychedelic Investor Survey, our fourth such survey. Here, we take a closer look at investors’...
A European Model: Robert Schoevers on the Continent’s Growing Psychedelic Research Agenda
Few have done more to shape Europe’s modern psychedelic research landscape than Professor Robert Schoevers, a psychiatrist and epidemiologist who is, among other things,...
Psychedelic Insights Playground
Come learn, connect, play & celebrate with healers, artists, & seekers at LA’s ultimate psychedelic community gathering!
The post Psychedelic Insights Playground appeared first on...
Brad Adams PhD – LAMPS
Brad Adams LAMPS (Los Angeles Psychedelic Society) joins Kyle to trace his path from PhD researcher to community builder. Brad shares how early work...
